Gilead toss­es $100M mile­stone chip in its fast-grow­ing gam­ble on new NASH drugs

Al­most two years to the day since Gilead $GILD struck a deal worth up to $470 mil­lion for Phenex’s FXR ag­o­nist pro­gram for NASH, the big biotech has fol­lowed up with a $100 mil­lion mile­stone pay­ment. Phenex ex­ecs say that Gilead has se­lect­ed GS-9674 to test in NASH, pri­ma­ry bil­iary cholan­gi­tis (PBC) and pri­ma­ry scle­ros­ing cholan­gi­tis.

The drug is now in Phase II in all three in­di­ca­tions.

Gilead has been in­vest­ing heav­i­ly in an ex­pand­ing NASH pipeline. Last No­vem­ber it added a $200 mil­lion mile­stone — on top of a $400 mil­lion up­front — to Nim­bus for an ACC in­hibitor now known as GS-0976.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.